Sustained glucagon-like peptide 1 expression from encapsulated transduced cells to treat obese diabetic rats

Journal of Bioscience and Bioengineering

Volumn 111, Issue 4, 2011, Pages 383-387

  Moralejo, Daniel ^a   Yanay, Ofer ^b   Kernan, Kelly ^b   Bailey, Adam ^b   Lernmark, Ake ^a   Osborne, William ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cells; Bioisolator; Diabetes; Encapsulated cells; GLP 1

Indexed keywords

BETA CELL; BIOISOLATOR; BLOOD GLUCOSE; CELL INFILTRATION; CHRONIC DISEASE; CONTROL LEVEL; CONTROL VALUES; DIABETES; DIABETIC RATS; ENCAPSULATED CELL; GLP-1; GLUCOSE TOLERANCE TEST; INDUSTRIALIZED COUNTRIES; INSULINOTROPIC EFFECTS; LEPTIN RECEPTORS; LONG TERM; MALE RATS; MULTIFOCAL; PUBLIC HEALTH; TYPE-2 DIABETES; VACUOLIZATION; VASCULAR SMOOTH MUSCLE CELLS;

CELL PROLIFERATION; GLUCOSE; HORMONES; MEDICAL PROBLEMS; PEPTIDES;

RATS;

CELLULOSE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL STRUCTURE; CELL VACUOLE; ENCAPSULATION; GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PROTEIN EXPRESSION; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MUSCLE, SMOOTH, VASCULAR; OBESITY; RATS; RATS, WISTAR; RECEPTORS, LEPTIN; TRANSDUCTION, GENETIC;

RATTUS;

EID: 79953321386     PISSN: 13891723     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2010.12.008     Document Type: Article

References (20)

1. Siegel K., Narayan K.M.V. The unite for diabetes campaign: overcoming constraints to find a global policy solution. Global Health 2008, 4:3.
2. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003, 46:3-19.
3. The Diabetes Control and Complications Trial Research Group Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann. Intern. Med. 1998, 128:517-523.
4. Sowers J.R. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am. J. Hypertens. 2003, 16:41-45.
5. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
6. Moralejo D.H., Hansen C.T., Treuting P., Hessner M.J., Fuller J.M., Van Yserloo B., Jensen R., Osborne W., Kwitek A.E., Lernmark A. Differential effects of leptin receptor mutation on male and female BBDR. Gimap5-/Gimap5-spontaneously diabetic rats. Physiol. Genomics 2010, 41:9-20.
7. Geary R.L., Clowes A.W., Lau S., Vergel S., Dale D.C., Osborne W.R.A. Gene transfer in baboons using prosthetic vascular grafts seeded with retrovirally-transduced smooth muscle cells: a model for local and systemic gene therapy. Hum. Gene Ther. 1994, 5:1213-1218.
8. Osborne W.R.A., Ramesh N., Lau S., Clowes M.M., Dale D.C., Clowes A.W. Gene therapy for long-term expression of erythropoietin in rats. Proc. Natl. Acad. Sci. USA 1995, 92:8055-8058.
9. Lejnieks D.V., Ramesh N., Lau S., Osborne W.R.A. Stomach implant for long term erythropoietin expression in rats. Blood 1998, 92:888-893.
10. Barry S.C., Ramesh N., Lejnieks D.V., Simonson W.T., Kemper L., Lernmark A., Osborne W.R.A. Glucose-regulated insulin expression in diabetic rats. Hum. Gene Ther. 2001, 12:131-139.
11. Yanay O., Flint L.Y., Brzezinski M., Barry S.C., Barton R.W., Osborne W.R.A. Long term erythropoietin gene expression from transduced cells in bioisolator devices. Hum. Gene Ther. 2003, 14:1587-1593.
12. Yanay O., Moralejo M., Kernan K., Brzezinski M., Fuller J.M., Barton R.W., Lernmark A., Osborne W.R. Prolonged survival and improved glycemia in BioBreeding diabetic rats after early sustained exposure to glucagon-like peptide 1. J. Gene Med. 2010, 12:538-544.
13. Moralejo D.H., Park H.A., Speros S.J., Macmurray A.J., Kwitek A.E., Jacob H.J., Lander E.S., Lernmark A. Genetic dissection of lymphopenia from autoimmunity by introgression of mutated Ian5 gene onto the F344 rat. J. Autoimmun. 2003, 21:315-324.
14. Deacon C.F. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes. Metab. 2007, 9:23-31.
15. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
16. Parsons G.B., Souza D.W., Wu H., Yu D., Wadsworth S.G., Gregory R.J., Armentano D. Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Ther. 2007, 14:38-48.
17. Hui H., Farilla L., Merkel P., Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur. J. Endocrinol. 2002, 146:863-869.
18. Lee Y., Kwon M.K., Kang E.S., Park Y.M., Choi S.H., Ahn C.W., Kim K.S., Park C.W., Cha B.S., Kim S.W., Sung J.K., Lee E.J., Lee H.C. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. J. Gene Med. 2008, 10:260-268.
19. Cummings B.P., Digitale E.K., Stanhope K.L., Graham J.L., Baskin D.G., Reed B.J., Sweet I.R., Griffen S.C., Havel P.J. Development and characterization of a novel rat model of type 2 diabetes mellitus: the UC Davis type 2 diabetes mellitus UCD-T2DM rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1782-R1793.
20. Marselli L., Thorne J., Ahn Y.-B., Omer A., Sgroi D.C., Libermann T., Otu H.H., Sharma A., Bonner-Weir S., Weir G.C. Gene expression of purified {beta}-cell tissue obtained from human pancreas with laser capture microdissection. J. Clin. Endocrinol. Metab. 2008, 93:1046-1053.